Our deep specialization in life science equity confers sector expertise and thereby positions us to outperform in this niche. Taking specialization to the next level, we concentrate our investment on the “growth biotech” stocks category. This allows us to capture the tremendous upsides in clinical stage and early product bioequities. Growth stocks tend to outperform...
To boost our gains, we leverage our expert edge in the forecasting of biotech binary events outcomes. As important catalytic developments for clinical stage biotech companies, these events entail either an FDA approval and significant clinical data report. Whenever a drug either passes through a major clinical hurdle or gains FDA approval, their stock is...
Known as Integrated BioSci Investing, our investment practice is inspired by various gurus, including Peter Lynch, Warren Buffett, Phillip Fisher, and Ben Graham. We integrate what we learned from those luminaries with various disciplines (i.e., medical, scientific, and market expertise) that are adapted specifically to biotech investing like a custom-made suit. In our approach, we...
Introduction Biotechnology, a rapidly evolving field that combines biology and technology, has the potential to revolutionize various industries and improve our quality of life. From healthcare to agriculture, biotech innovations are transforming the way we live and work. As an investor, recognizing the opportunities in this sector can be highly rewarding. In this blog post,...